title: Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP.
abstract: BACKGROUND
  The experimental observation that plasma from TTP patients sometimes exhibits a protein which can cause platelet agglutination, and that such agglutination can be inhibited in vitro by the use of IgG led some authors to treat plasma exchange-resistant TTP patients with high-dose IgG (HDIgG).
  
  
  METHODS
  We report the results obtained with HDIgG treatment in 17 patients retrospectively examined by the Italian Cooperative Group for the study of TTP: 6 males and 11 females, mean age was 31.7 years for the women (range: 20-65) and 44.6 for the men (range: 26-66). In all cases HDIgG administration was combined with other treatment modalities.
  
  
  RESULTS
  Of the 17 patients, 7 died from disease progression (41.1%), 2 achieved partial remission (11.7%) and the remaining 8 achieved complete remission (47%). Of the 10 cases (58.8%) with a positive response, only in 4 did the addition of HDIgG seem to produce significant improvement. All efforts made to characterize the subgroup of patients who responded to HDIgG and compare them with the non responders failed.
  
  
  CONCLUSIONS
  Although our results do not unquestionably demonstrate the role of HDIgG in the treatment of TTP, they suggest a possible role for HDIgG in the treatment of those rare plasma exchange-resistant TTP cases.
authors.affiliation: Ospedale Nuovo di Torrette, Università di Ancona, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Centurioni
authors.forename: E
authors.initials: E
authors.lastname: Bobbio-Pallavicini
authors.forename: C
authors.initials: C
authors.lastname: Porta
authors.forename: F
authors.initials: F
authors.lastname: Rodeghiero
authors.forename: L
authors.initials: L
authors.lastname: Gugliotta
authors.forename: A
authors.initials: A
authors.lastname: Billio
authors.forename: F
authors.initials: F
authors.lastname: Tacconi
authors.forename: E
authors.initials: E
authors.lastname: Ascari
mesh_terms: D000328:Adult; D000368:Aged; D001241:Aspirin / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D001241:Aspirin